Home › Funds › VALLEY FORGE INVESTMENT CONSULTANTS INC ADV › SPRY
VALLEY FORGE INVESTMENT CONSULTANTS INC ADV position in SPRY
ARS PHARMACEUTICALS INC · Health Care
VALLEY FORGE INVESTMENT CONSULTANTS INC ADV reported holding 83,225 shares of SPRY (ARS PHARMACEUTICALS INC) in its Q2 2026 13F filing — a position valued at US$667K, representing 0.17% of its reported portfolio and ranking #43 among its reported holdings. VALLEY FORGE INVESTMENT CONSULTANTS INC ADV has disclosed SPRY holdings in 8 of the last 8 reported quarters, going back to Q3 2024.
Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR
How VALLEY FORGE INVESTMENT CONSULTANTS INC ADV's SPRY position evolved
VALLEY FORGE INVESTMENT CONSULTANTS INC ADV first disclosed a stake in SPRY in Q3 2024 at 83,225 shares (US$1.2M). The position peaked in Q2 2025 at 83,225 shares, worth US$1.5M. Across 8 filings, VALLEY FORGE INVESTMENT CONSULTANTS INC ADV held the position steady without any share-count change. The most recent filing (Q2 2026) shows 83,225 shares valued at US$667K.
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q3 2024 | 83.22K | $1.21M | New |
| Q4 2024 | 83.22K | $878.02K | Hold |
| Q1 2025 | 83.22K | $1.05M | Hold |
| Q2 2025 | 83.22K | $1.45M | Hold |
| Q3 2025 | 83.22K | $836.41K | Hold |
| Q4 2025 | 83.22K | $969.57K | Hold |
| Q1 2026 | 83.22K | $668.30K | Hold |
| Q2 2026 | 83.22K | $666.63K | Hold |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About SPRY and 13F data
SPRY (ARS PHARMACEUTICALS INC) is a Health Care company. 25 other funds we track also report a position in SPRY — the largest reported positions include RA CAPITAL MANAGEMENT, L.P. (US$87.0M), Rubric Capital Management LP (US$68.4M), ORBIMED ADVISORS LLC (US$66.4M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding SPRY
- RA CAPITAL MANAGEMENT, L.P. 10.86M sh · $87.00M · Q2 2026
- Rubric Capital Management LP 8.54M sh · $68.41M · Q2 2026
- ORBIMED ADVISORS LLC 8.29M sh · $66.39M · Q2 2026
- DEERFIELD MANAGEMENT COMPANY, L.P. 7.50M sh · $60.11M · Q2 2026
- Tyro Capital Management LLC 4.46M sh · $35.72M · Q2 2026
- SR ONE CAPITAL MANAGEMENT, LP 4.01M sh · $32.14M · Q2 2026
- GENERAL AMERICAN INVESTORS CO INC 1.13M sh · $9.08M · Q2 2026
- Third Point 1.00M sh · $8.01M · Q2 2026
- Third Point LLC 1.00M sh · $8.01M · Q2 2026
- Tejara Capital Ltd 607.04K sh · $4.86M · Q2 2026
More on VALLEY FORGE INVESTMENT CONSULTANTS INC ADV
FAQ
How long has VALLEY FORGE INVESTMENT CONSULTANTS INC ADV held SPRY?
VALLEY FORGE INVESTMENT CONSULTANTS INC ADV has disclosed SPRY holdings in 8 of the last 8 reported quarters, going back to Q3 2024.
What is VALLEY FORGE INVESTMENT CONSULTANTS INC ADV's current position in SPRY?
As of Q2 2026, VALLEY FORGE INVESTMENT CONSULTANTS INC ADV holds 83.22K shares of SPRY (ARS PHARMACEUTICALS INC), valued at $666.63K, representing 0.17% of its reported portfolio and ranking #43.
Has VALLEY FORGE INVESTMENT CONSULTANTS INC ADV been buying or selling SPRY?
In the latest 13F filing (Q2 2026), VALLEY FORGE INVESTMENT CONSULTANTS INC ADV held unchanged its position in SPRY. The position peaked in Q2 2025 at 83.22K shares.
Which other funds hold SPRY?
Other major institutional holders of SPRY include RA CAPITAL MANAGEMENT, L.P., Rubric Capital Management LP, ORBIMED ADVISORS LLC, among 25 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.